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Objective To investigate changes in the incidence and
treatment of prostate cancer over the period in which
new diagnostic tools were introduced and the attitude
towards treatment was changing.
Patients and methods Information on the extent of
disease and treatment of patients diagnosed with
prostate cancer within the Rotterdam region was
retrieved from the Rotterdam Cancer Registry.
Results In the period 1989–95, 4344 patients were
diagnosed with prostate cancer and the age-standar-
dized incidence increased from 62 to 125 per 100 000
men. This increase mainly comprised tumours
localized to the prostate, while the incidence of
advanced cancers remained stable. The proportion
of poorly differentiated tumours decreased from 33%
in 1989 to 24% in 1995. In the same period the
number of patients receiving radiotherapy increased
from 80 to 258, while the annual number of radical
prostatectomies rose from 17 to 159. Radiotherapy
was the preferred type of treatment in patients over
70 years of age, whereas radical prostatectomy was
used more frequently in younger patients with
localized tumours.
Conclusion While the value of screening for prostate
cancer remains in debate, incidence and treatment
patterns are changing rapidly. Information on pat-
terns of care is needed to interpret future mortality
data and to plan resources for adequate health care.
Keywords prostate cancer, incidence, radical prostatec-
tomy, radiotherapy, PSA
Introduction
In many western countries prostate cancer is rapidly
becoming the most frequent cancer in men, as it already
is in the USA [1,2]. Within Europe, the highest incidence
rates are reported from Sweden, where prostate cancer
has become more common than lung cancer [3]. Other
European countries showing high incidence rates are
Austria, Finland and the Netherlands. The age-standard-
ized incidence of prostate cancer in the USA is about two
to three times higher than in Europe [2, 4]. During the
1970s and 1980s the age-standardized incidence in
Europe increased by 5–25% every 5 years [5]. In the USA
the increase was 15–25% every 5 years, until there was
an ‘epidemic’ increase in the last decade; increases from
40–300% have recently been reported [6–10].
This ‘epidemic’ of prostate cancer has been induced by
the introduction of new diagnostic methods [9, 10].
Because there are no curative treatment options for
patients with advanced cancer, scientific attention has
focused on the diagnosis and control of prostate cancer at
an early stage. New tools such as TRUS and the biopsy
gun facilitated the diagnosis of prostate cancer by needle
biopsy. In the last decade the introduction of the PSA
assay has markedly increased the opportunities to detect
early prostate cancer. Several randomized studies are
currently assessing the value of the PSA assay as a
screening instrument. In the absence of conclusive
results from these studies, the value of screening for
prostate cancer remains controversial.
It is conceivable that the harm caused by over-
diagnosis and subsequent over-treatment may over-
shadow the benefits of early detection [11,12].
Advocates of early detection have indicated that the
survival after aggressive treatment of localized carcino-
mas is good [13,14], albeit that several observational
studies show reasonable results with a watchful-waiting
policy [12,15,16].
Consequently, there is a worldwide variation in the
management of localized prostate cancer. In the USA,
radical prostatectomy is becoming as popular as radio-
therapy [6]. In some countries, radiotherapy is more
popular [17] whereas in other countries watchful
waiting is preferred [18], or the diagnosis of asympto-
matic cancers considered not worthwhile [19]. To
investigate the treatment policy for localized prostate
cancer in the Rotterdam region in a period of increasing
incidence, we analysed population-based data from theAccepted for publication 2 November 1999
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Rotterdam Cancer Registry. The Rotterdam region is
of particular interest because the city is one of the
participants in the European Randomised Screening
study for Prostate Cancer (ERSPC) [20].
Patients and methods
Information about incidence and treatment of patients
with prostate cancer was obtained from the Rotterdam
Cancer Registry; the registry was started in 1982 and
covers the south-western part of The Netherlands. Since
1989, registration has been complete in the central part
of the registration area, thus allowing the calculation of
population-based incidence rates. This central part of the
Rotterdam region comprises <1.5 million inhabitants;
of the 750 000 men, <100 000 are aged 55–69 years,
25 000 are aged 70–74 and 30 000 are older than
74 years.
In 1992 the Rotterdam section of the ERSPC
commenced [21]. Men living in Rotterdam and aged
55–75 years were invited to participate in a study in
which they would be randomized between a screening
arm and a control group. The men in the screening arm
provided blood for PSA assay, with a 4-year screening
interval. At the end of 1995 the screening arm of the
study comprised <4000 men (<3% of the respective
population in that age group). The cancer registry
receives information on whether men have been
diagnosed after regular care or after screening.
All patients with prostate cancer diagnosed from 1989
to 1996 were included (n=4344), except those with
tumours incidentally found at autopsy (n=33). Newly
diagnosed patients with cancer are notified through notes
from pathology laboratories and hospital discharge
diagnoses. Trained registration clerks collect data from
the clinical case-notes. Prostate cancers diagnosed from
1989 to 1993 were classified according to the 1987 rules
of the UICC. Tumours diagnosed after 1992 were
classified according to the UICC classification of 1992.
The main change was the introduction of the T1c group
for tumours identified as a result of PSA testing. For the
present study, the clinical TNM information was
combined, to group the tumours into four stages
(Table 1). Clinical stages 1–3 can be considered to be
potentially curable and are termed ‘localized carcino-
mas’, whereas stage 4 is termed ‘advanced’. Tumours for
which information on the clinical T-status was missing
were referred to as stage X. The grade of differentiation of
the tumours was coded as well-differentiated (grade 1 or
Gleason score 2–4), moderately differentiated (grade 2 or
Gleason score 5–7), poorly or undifferentiated (grade 3/4
or Gleason score 8–10) [22]. Tumour grade was based on
the histological examination of the prostatectomy or
biopsy specimen. Information on initial treatment was
gathered for all patients. Only radical prostatectomies
were evaluated as the surgical treatment. Transurethral
resection and open prostatectomy for obstructive com-
plaints with no resection of the lymph nodes were
disregarded. Radiotherapy was only indicated when
directed at the primary tumour with curative intent.
Patients receiving postoperative radiotherapy (n=23)
were included in the surgery group. Since 1993 the PSA
level at diagnosis has been recorded. Within the region,
several kits for PSA determination have been used, but
the Hybritech assay (Tandem, Hybritech Europe SA,
Liege, Belgium) was the most common. Cases with an
unknown PSA value (n=275) were excluded from the
analysis of PSA distribution.
Incidence rates were calculated by mode of detection
(diagnosed through regular care or in the screening arm
of the ERSPC). Age-standardization was conducted
according to the European standard. Distributions of
tumour stage and grade of differentiation were examined
by year of diagnosis. Differences in grade distribution
were analysed with the Pearson chi-square statistic. The
distribution of PSA values was analysed for the total
group and by tumour stage. The distribution of log PSA
was evaluated statistically using an ANOVA. The evalua-
tion of curative treatment for localized prostate cancer
comprised overall trends and trends in different age
groups. Surgery and radiotherapy were evaluated by age
group, period of diagnosis and tumour stage.
Results
The age standardized incidence rate of prostate cancer
increased from 62 to 125 per 100 000 men, surpassing
lung cancer as the most frequent form of cancer in the
region. Only a small proportion of these cancers had been
detected by the ERSPC study (Fig. 1). The proportion of
cases detected by screening was 16% in 1995.
The increase was mainly in tumours that were
confined to the prostate, especially those classified as
stage 2 (Fig. 2). The annual number of stage 2 lesions
increased from 134 in 1989 to 573 in 1995, comprising
29% and 58% of all tumours. Surprisingly, there was
only a limited increase of stage 1 tumours, although the
proportion of T1c tumours increased from 4% in 1993 to
Table 1 Stage grouping according to the clinical TNM stage
Stage group cT cN cM
1 0,1,1a,1b,1c 0,X 0,X
2 2,2a,2b,2c 0,X 0,X
3 3,3a,3b,3c 0,X 0,X
4 4,4a,4b 1,2,3 1,1a,1b,1c
X X 0,X 0,X
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9% in 1995 (data not shown). The number of advanced
cancers remained stable throughout the study period, but
declined proportionally from 30% to 16%.
Despite the marked change in stage, the change in
distribution of tumour grade was less apparent. In 1995
the proportion of poorly differentiated cancers was
23.7%, compared with 33.3% in 1989, whereas the
proportion of well-differentiated cancers increased from
20.0% to 33.6% (P<0.001; Table 2). The median PSA
value decreased from 27.0 ng/mL in 1993 to 15.1 ng/mL
in 1995 (P<0.001). There were no significant changes
in PSA distribution within separate stage groups, except
for a small decrease in the median PSA level for the group
of stage 2 tumours, from 15.2 in 1993 to 13.0 in 1995
(P<0.001; Table 3).
The frequency of patients choosing definitive treatment
changed considerably. From 1989 to 1995 the annual
number of patients receiving radiotherapy increased from
80 to 258, whereas the annual number of radical
prostatectomies rose from 17 to 159 (Fig. 3); 95% of the
patients receiving curative treatment had localized
disease. Within the latter group, the proportion receiving
curative treatment increased from 25.7% in 1989 (4.5%
surgery and 21.2% radiotherapy) to 52.1% in 1995
(20.1% surgery and 32.0% radiotherapy).
The largest increase of the proportion of patients
receiving curative treatment was in patients <70 years
old (Fig. 4). For patients aged 70–74 years, there was also
a considerable increase, but in patients over 74 years
of age the proportion receiving curative treatment
remained stable at about 20%. Radiotherapy was the
preferred treatment in patients >70 years of age,
independent of stage (Table 4). For younger patients,
radical prostatectomy has become the most common type
of definitive treatment for stage 2 tumours. Tumour
differentiation had a small influence on the frequency of
curative treatment in patients with localized cancer.
Treatment rates for patients with well, moderately and
poorly differentiated tumours were 37%, 51% and 46%,
respectively.
Discussion
These results show that the treatment policy for localized
prostate cancer has changed considerably. As in recent
reports from the USA, the proportion of patients receiving
definitive treatment has increased and radical prosta-
tectomy has become the preferred treatment for patients
<70 years old. Despite the growing role of surgery [23],
radiotherapy has maintained a key role in the manage-
ment of localized prostate cancer [6,24].
Compared with patterns of care in the USA, several
differences emerge. First, the age threshold for prosta-
tectomy in the Rotterdam region is <70 years, as against
75 years in the USA. Apparently, risks and benefits are
considered to be different for men aged 70–75 and
radiotherapy is still preferred by the regional urologists.
Second, prostatectomy is mainly performed in patients
with stage 2 disease, whereas studies in the USA report
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Fig. 1. The trend in incidence rates (per 100 000 men, age-adjusted
to the European population) according to the mode of detection
(ERSPC, light red; regularly detected by the general health care
system, light green).
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Fig. 2. The trend in the number of newly diagnosed carcinomas
according to stage group (1 green; 2 light green; 3 red; 4 light red; X
black).
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higher proportions of stage 3 cancers [25]. However,
results related to stage are difficult to compare because
the Rotterdam data refer to clinical stage, whereas USA
registries combine information on clinical and patholo-
gical stage of disease. Moreover, clinical staging is
subjective and additional staging procedures tend to
vary both nationally and internationally. For clinical
stage 3, radiotherapy is apparently preferred over
surgery, although some tumours may prove to be
confined to the prostate at operation. Whether radio-
therapy for stage 3 should be considered as ‘given with
curative intent’ is open to debate, but the 5-year survival
for stage 3 cancers is 70% in the Netherlands [26]. A
third difference from the situation in the USA is that in
the Rotterdam region more patients are treated expec-
tantly, especially in the oldest group. The efficacy of
aggressive treatment for localized prostate cancer is still
debated as the 10-year survival may be similar with
initially conservative management [15, 16]. Within
the Rotterdam region, guidelines advocate expectant
management for men who have a life expectancy of <10
years or an incidental finding of a well-differentiated
tumour.
Several developments have contributed to the major
rise in prostatectomy rates. The introduction of the PSA
assay, supported by the introduction of TRUS and TRUS-
guided transrectal needle biopsies, has enabled the
diagnosis of prostate cancer to be made at a stage
where it is still curable. Although it is advisable to refrain
from screening until the results from controlled rando-
mized trials, e.g. the ERSPC in Europe and the PCLO in the
USA, have been analysed and published, the PSA assay
has evidently become routine in clinical practice. This has
led to a dramatic increase in the incidence of prostate
cancer. Even after excluding ERSPC-detected cases, the
incidence still increased by 70% during the 7-year study
Table 2 The tumour grade of differentiation, n (%), according to year of diagnosis
Year Grade 1 Grade 2 Grade 3/4 Grade unknown
1989 94 (20.0) 171 (36.3) 157 (33.3) 49 (10.4)
1990 88 (19.2) 153 (33.3) 178 (38.8) 40 (8.7)
1991 117 (23.1) 172 (33.9) 173 (34.1) 45 (8.9)
1992 163 (28.0) 214 (36.8) 155 (26.6) 50 (8.6)
1993 177 (27.8) 217 (34.1) 197 (30.9) 46 (7.2)
1994 219 (28.7) 270 (35.4) 220 (28.9) 53 (7.0)
1995 311 (33.6) 332 (35.9) 219 (23.7) 64 (6.9)
Table 3 The distribution of PSA values (ng/mL) by year of diagnosis and stage
Percentile
Stage/year 10 25 50 75 90
Total
1993 4.6 10.2 27.0 83.0 315.2
1994 4.1 8.6 21.1 58.0 182.4
1995 4.0 7.1 15.1 45.0 179.6
1
1993 1.6 4.8 9.4 37.0 67.0
1994 1.8 3.4 7.7 14.0 31.1
1995 2.8 5.1 8.0 16.2 35.4
2
1993 4.5 8.7 15.2 41.8 89.5
1994 4.2 8.5 18.0 40.3 89.0
1995 3.6 6.7 13.0 29.0 54.0
3
1993 4.8 14.7 29.5 69.1 195.8
1994 5.4 10.4 23.6 55.8 134.8
1995 4.4 8.0 24.5 62.0 140.4
4
1993 20.8 45.5 108.5 378.8 1000
1994 9.6 33.8 92.8 340.5 1000
1995 13.0 51.0 160.0 498.0 1320
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period. Another trend that should not be overlooked is
the growing popularity of radical prostatectomy among
urologists. Since the nerve-sparing procedure has
improved, the outcome is considered more acceptable
for potency and continence. In addition, more urologists
have learned to carry out radical prostatectomies during
residency and they are obviously more inclined to
recommend therapeutic interventions which reflect
their particular discipline. A widespread belief has
grown that the results of radical prostatectomy in
terms of long-term survival are superior to the other
treatment modalities such as radiation and watchful
waiting [27].
The clinical significance of screening-detected
tumours, and therefore the desirability of aggressive
treatment of these tumours, is much debated. Prostate
cancer may be viewed as a pyramidal ‘iceberg of disease’
[28]. The tip of clinical or symptomatic disease projects
above the surface, but there is a huge base of
asymptomatic lesions which, under ordinary circum-
stances, lie hidden. Because this cancer base expands
below the surface, screening tests can detect many
cancers. With current knowledge it is not possible to
predict whether these early cancers will become sympto-
matic or might have remained hidden as latent tumours.
In spite of the above, the present results suggest that
clinically relevant tumours are being diagnosed. The
increase in detection was not confined to T1c tumours, as
might have been expected, but mainly comprised stage 2
cancers, i.e. these tumours were already palpable and/or
visible on TRUS or CT. Moreover, if these localized
tumours were to be less aggressive, the stage shift would
be reflected by a proportional decrease in poorly
differentiated tumours. This idea is not supported by
the minor shift from poorly differentiated to well-
differentiated tumours, although it was statistically
significant because the sample was large. Also, within
the various stage groups, the median PSA values only
showed a minimal decline, suggesting that these localized
tumours would probably behave aggressively.
In conclusion, the incidence and treatment patterns of
prostate cancer are changing rapidly, and this will
hopefully lead to a decrease in mortality. Future trends in
mortality will be hard to explain without information on
incidence patterns and treatment policy. Unfortunately,
information on patterns of care within European
countries is largely lacking. Although surveys among
urologists may also be informative [28], population-
based data, like those presented here, and the pattern-of-
care studies in the USA, are urgently needed to interpret
trends in mortality, and to plan and organize adequate
healthcare.
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carcinomas who received curative therapy, by age group (<74
years, green; 70–74, red; >74, light green).
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